Nomogram to Predict Progression-free Survival in Patients with Well-differentiated, Stage IV Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues: Data of TRASGU-GETNE Study

被引：0

作者：

Jimenez-Fonseca, P. ^{[1
]}

Alonso, V ^{[2
]}

Riesco, M. C. ^{[3
]}

Custodio, A. ^{[4
]}

Molina-Cerrillo, J. ^{[5
]}

Sanchez Canovas, M. ^{[6
]}

Benavent, M. ^{[7
]}

Hernando Cubero, J. ^{[8
]}

La Casta, A. ^{[9
]}

Lopez, C. ^{[10
]}

Marazuela Azpiroz, M. ^{[11
]}

Carmona-Bayonas, A. ^{[12
]}

机构：

[1] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain

[2] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain

[3] Hosp Univ Doce Octubre, Dept Med Oncol, Madrid, Spain

[4] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain

[5] Hosp Univ Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[6] Hosp Univ Morales Meseguer, Dept Med Oncol, Murcia, Spain

[7] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain

[8] Hosp Univ Vall dHebron, Dept Med Oncol, Barcelona, Spain

[9] Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain

[10] Hosp Univ Marques Valdecilla, Dept Med Oncol, Santander, Spain

[11] Complejo Hosp La Princesa, Dept Endocrinol, Madrid, Spain

[12] Univ Murcia, Hosp Univ Morales Meseguer Murcia, Dept Med Oncol, UMU,IMIB, Murcia, Spain

来源：

NEUROENDOCRINOLOGY | 2019年 / 108卷

关键词：

cox regression; prognosis; registry; tool;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

D28

引用

页码：67 / 67

页数：1

共 31 条

[1] Development and internal validation of a predictive nomogram of progression-free survival in well-differentiated stage IV gastroenteropancreatic neuroendocrine tumours treated with somatostatin analogues: GETNE-TRASGU study
Garcia-Carbonero, R.
Alonso, V.
Capdevila, J.
Sanchez Canovas, M.
Alonso, T.
Benavent, M.
Custodio, A.
Crespo Herrero, G.
Lopez, C.
Hernando, J.
Riesco Martinez, M. C.
Escudero, P.
Gallego Plazas, J.
Marazuela, M.
Diaz, J. A.
Llanos-Munoz, M.
La Casta, A.
Percovich, J. C.
Jimenez-Fonseca, P.
Carmona-Bayonas, A.
ANNALS OF ONCOLOGY, 2018, 29 : 471 - 471
[2] Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Carmona-Bayonas, Alberto
Jimenez-Fonseca, Paula
Lamarca, Angela
Barriuso, Jorge
Castano, Angel
Benavent, Marta
Alonso, Vicente
Riesco-Martinez, Maria del Carmen
Alonso-Gordoa, Teresa
Custodio, Ana
Sanchez Canovas, Manuel
Hernando Cubero, Jorge
Lopez, Carlos
Lacasta, Adelaida
Fernandez Montes, Ana
Marazuela, Monica
Crespo, Guillermo
Escudero, Pilar
Diaz, Jose Angel
Feliciangeli, Eduardo
Gallego, Javier
Llanos, Marta
Segura, Angel
Vilardell, Felip
Percovich, Juan Carlos
Grande, Enrique
Capdevila, Jaume
Valle, Juan W.
Garcia-Carbonero, Rocio
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (28) : 2571 - +
[3] Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
Jimenez-Fonseca, P.
Carmona-Bayonas, A.
Lamarca, A.
Barriuso, J.
Castano, A.
Hernando, J.
Lopez, C.
Marazuela, M.
Crespo, G.
Escudero, P.
Capdevila, J.
Garcia Carbonero, R.
NEUROENDOCRINOLOGY, 2020, 110 : 230 - 230
[4] Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors
Dhall, Deepti
Mertens, Richard
Bresee, Catherine
Parakh, Rugvedita
Wang, Hanlin L.
Li, Marissa
Dhall, Girish
Colquhoun, Steven D.
Ines, Delma
Chung, Fai
Yu, Run
Nissen, Nicholas N.
Wolin, Edward
HUMAN PATHOLOGY, 2012, 43 (04) : 489 - 495
[5] Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo
Van Cutsem, E.
Seitz, J. F.
Raoul, J.
Valle, J. W.
Faivre, S. J.
Patyna, S.
Klademenos, D.
Lu, D.
Chao, R. C.
Raymond, E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[6] Evaluation of Progression-Free Survival by Blinded Independent Central Review in Patients With Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors Treated With Sunitinib or Placebo
Hammel, Pascal
Castellano, Daniel
Van Cutsem, Eric
Niccoli, Patricia
Faivre, Sandrine
Patyna, Shem
Klademenos, Deno
Lu, Dongrui Ray
Chao, Richard
Raymond, Eric
PANCREAS, 2011, 40 (02) : 327 - 327
[7] Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
Pusceddu, Sara
Vernieri, Claudio
Di Maio, Massimo
Marconcini, Riccardo
Spada, Francesca
Massironi, Sara
Ibrahim, Toni
Brizzi, Maria Pia
Campana, Davide
Faggiano, Antongiulio
Giuffrida, Dario
Rinzivillo, Maria
Cingarlini, Sara
Aroldi, Francesca
Antonuzzo, Lorenzo
Berardi, Rossana
Catena, Laura
De Divitiis, Chiara
Ermacora, Paola
Perfetti, Vittorio
Fontana, Annalisa
Razzore, Paola
Carnaghi, Carlo
Davi, Maria Vittoria
Cauchi, Carolina
Duro, Marilina
Ricci, Sergio
Fazio, Nicola
Cavalcoli, Federica
Bongiovanni, Alberto
La Salvia, Anna
Brighi, Nicole
Colao, Annamaria
Puliafito, Ivana
Panzuto, Francesco
Ortolani, Silvia
Zaniboni, Alberto
Di Costanzo, Francesco
Torniai, Mariangela
Bajetta, Emilio
Tafuto, Salvatore
Garattini, Silvio Ken
Femia, Daniela
Prinzi, Natalie
Concas, Laura
Lo Russo, Giuseppe
Milione, Massimo
Giacomelli, Luca
Buzzoni, Roberto
Delle Fave, Gianfranco
GASTROENTEROLOGY, 2018, 155 (02) : 479 - +
[8] Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors
Faggiano, A.
Ramundo, V
Del Prete, M.
Marotta, V
Marciello, F.
Camera, L.
Napolitano, V
De Luca, L.
Lombardi, G.
Colao, A.
NEUROENDOCRINOLOGY, 2012, 96 : 28 - 29
[9] The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors.
Delavault, Patrick
Caplin, Martyn E.
Liyange, Nilani
Blumberg, Joelle
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrinc tumor receiving everolimus plus somatostatin analog treatment
Pusceddu, Sara
Buzzoni, Roberto
Giacomelli, Luca
Mazzaferro, Vincenzo
Concas, Laura
Mllione, Massimo
Formisano, Barbara
D'Autilla, Elise
Festinese, Fabrizio
De Braud, Filippo G.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 →